Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Fetal safety of calcium channel blockers

Fatoumah Alabdulrazzaq and Gideon Koren
Canadian Family Physician July 2012, 58 (7) 746-747;
Fatoumah Alabdulrazzaq
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Koren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question Many of my pregnant or lactating patients are taking calcium channel blockers (CCBs) for hypertension. How safe is maternal use of CCBs for fetuses and nursing infants?

Answer Generally, CCBs have not been shown to increase teratogenic risk. Information regarding the safety of CCBs during lactation is limited, although they are not likely to pose a risk to the nursing infant.

Calcium channel blockers (CCBs) are commonly used during pregnancy and lactation to treat hypertension, arrhythmia, and preeclampsia. They have also been used as tocolytic agents to prevent premature labour and its complications.

Population-based data from 5 health maintenance organizations in the United States were used to study the risks of perinatal complications and congenital defects among infants exposed in utero to CCBs or β-blockers. Calcium channel blocker use in the third trimester was associated with increased risk of neonatal seizures, jaundice, and hematologic disorders (relative risk [RR] 3.6, 95% CI 1.3 to 10.4). The risk of neonatal convulsions was in part attributed to the placental transfer of CCBs, leading to a decrease in infants’ cellular calcium levels.1 There was no increase in risk of congenital anomalies in either group of infants. The risk of one or more malformations was not elevated in the group of infants exposed to CCBs (RR 0.96, 95% CI 0.47 to 1.97).1

The Motherisk program reported no increased teratogenic risk of perinatal complications among 78 women exposed to CCBs in the first trimester. Maternal hypertension was the most important factor responsible for babies with low birth weights in this group.2

The Swedish Medical Birth Register studied a cohort of 1418 pregnancies in which the mothers took anti-hypertensive drugs in early pregnancy; in 217 pregnancies, the mothers took CCBs. Three babies were born with congenital heart defects (RR 1.15). The study concluded that there was little drug specificity in the association between maternal use of antihypertensive drugs and increased risk of infant cardiovascular defects.3

A Hungarian case-control study identified 22 865 infants with congenital abnormalities and 31 151 healthy population control babies between 1980 and 1996; 586 mothers had been exposed to CCBs during pregnancy compared with 907 mothers in the control group. The overall prevalence ratios for 17 congenital abnormalities varied between 1.1 and 1.4, and there was no significant increase in risk of congenital abnormalities.4

All CCBs pass into the breast milk in small amounts.5–7 Both LactMed (Drugs and Lactation Database) and the American Academy of Pediatrics conclude that this class of medications is compatible with breastfeeding.8 It is advisable to follow up with any exposed infant for signs of hypotension.

Calcium channel blockers can be safely used during pregnancy and breastfeeding.

Notes

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Dr Alabdulrazzaq is a member and Dr Koren is Director of the Motherisk Program. Dr Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.

Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Davis RL,
    2. Eastman D,
    3. McPhillips H,
    4. Raebel MA,
    5. Andrade SE,
    6. Smith D,
    7. et al
    . Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011;20(2):138-45. Epub 2010 Nov 15.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Magee LA,
    2. Schick B,
    3. Donnenfeld AE,
    4. Sage SR,
    5. Conover B,
    6. Cook L,
    7. et al
    . The safety of calcium channel blockers in human pregnancy: a prospective, multi-center cohort study. Am J Obstet Gynecol 1996;174(3):823-8.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lennestål R,
    2. Otterblad Olausson P,
    3. Källén B
    . Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65(6):615-25. Epub 2009 Feb 7.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sørensen HT,
    2. Czeizel AE,
    3. Rockenbauer M,
    4. Steffensen FH,
    5. Olsen J
    . The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 2001;80(5):397-401.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ghanem FA,
    2. Movahed A
    . Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther 2008;26(1):38-49. Epub 28 Jun 2008.
    OpenUrlPubMed
    1. Shannon ME,
    2. Malecha SE,
    3. Cha AJ
    . Calcium channel antagonists and lactation: an update. J Hum Lact 2000;16(1):60-4.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Solans C,
    2. Aramayona JJ,
    3. Bregante MA,
    4. Fraile LJ,
    5. Rueda S,
    6. Garcia MA
    . Pharmacokinetics of verapamil in lactating rabbits: prediction of verapamil distribution into rabbit milk. Gen Pharmacol 2000;34(4):237-43.
    OpenUrlPubMed
  7. ↵
    American Academy of Pediatrics Committee on Drugs: the transfer of drugs and other chemicals into human milk. Pediatrics 1994;93(1):137-50.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 58 (7)
Canadian Family Physician
Vol. 58, Issue 7
1 Jul 2012
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fetal safety of calcium channel blockers
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fetal safety of calcium channel blockers
Fatoumah Alabdulrazzaq, Gideon Koren
Canadian Family Physician Jul 2012, 58 (7) 746-747;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Fetal safety of calcium channel blockers
Fatoumah Alabdulrazzaq, Gideon Koren
Canadian Family Physician Jul 2012, 58 (7) 746-747;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire